Effect of tafluprost on the diurnal intraocular pressure fluctuations in patients with primary open-angle glaucoma
https://doi.org/10.25700/NJG.2018.04.08
Abstract
Glaucoma therapy is directed towards intraocular pressure stabilization. Pathological diurnal fluctuations of intraocular pressure (IOP), as well as its average value during 24 hours, is a significant risk factor or primary open-angle glaucoma (POAG) progression. Currently, a whole range pharmacological drugs is used for IOP correction. They differ in hypotensive effect degree, which, in turn, can depend on the time of administration. Tafluprost, a prostaglandin analogue, has a significant hypotensive effect and can effectively decrease diurnal IOP fluctuations amplitude in patients with POAG.
About the Authors
S. Yu. Petrov
Scientific Research Institute of Eye Diseases.
Russian Federation
Russian Federation
Med.Sc.D., leading research associate of Glaucoma Dept.
11А Rossolimo st., Moscow, 119021.
A. V. Volzhanin
Scientific Research Institute of Eye Diseases.
Russian Federation
Russian Federation
postgraduate student.
11А Rossolimo st., Moscow, 119021.
M. V. Kravchik
Scientific Research Institute of Eye Diseases.
Russian Federation
Russian Federation
postgraduate student.
11А Rossolimo st., Moscow, 119021.
Yu. V. Mazurova
Scientific Research Institute of Eye Diseases.
Russian Federation
Russian Federation
M.D., chief of III Surgical Dept.
11А Rossolimo st., Moscow, 119021.
L. M. Saparova
Scientific Research Institute of Eye Diseases.
Russian Federation
Russian Federation
M.D.
11А Rossolimo st., Moscow, 119021.
References
1. Flaxman S.R., Bourne R.R.A., Resnikoff S., Ackland P. et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017; 5(12):e1221-e1234. doi: 10.1016/S2214-109X(17)30393-5.
2. Nesterov A.P. Glaukoma. [Glaucoma]. Moscow, Medicine Publ; 1995. [In Russ.].
3. Cedrone C., Mancino R., Cerulli A., Cesareo M., Nucci C. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog Brain Res. 2008; 173:3-14. doi: 10.1016/S0079-6123(08)01101-1.
4. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121(11):2081-2090. doi: 10.1016/j.ophtha.2014.05.013.
5. Nesterov A.P., Alekseev V.N., Alekseev I.B. Amirov A.N., Astakhov Yu.S., Balalin S.V. Nacional’noe rukovodstvo po glaukome dlya prak- tikuyushchih vrachej. [National guidelines on glaucoma for practicing physicians, 3rd edition]. Moscow, GEOTAR-Media Publ.; 2015: 457. [In Russ.].
6. European Glaucoma Society. Terminology and guidelines for glau¬coma. 4th ed: Savona, Italy: PubliComm; 2014.
7. Heijl A., Leske M.C., Bengtsson B., Hyman L. et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120(10):1268-1279.
8. Glaucoma. Nacional’noe rukovodstvo [National guidelines]. Edited by E.A. Egorov. Moscow, GEOTAR-Media Publ; 2013: 824. [In Russ. ].
9. Prum B.E., Jr., Rosenberg L.F., Gedde S.J., Mansberger S.L. et al. Primary open-angle glaucoma preferred practice pattern (R) Guide¬lines. Ophthalmology. 2016; 123(1):P41-P111. doi: 10.1016/j.ophtha. 2015.10.053.
10. Schmidl D., Schmetterer L., Garhofer G., Popa-Cherecheanu A. Phar¬macotherapy of glaucoma. J Ocul Pharmacol Ther. 2015; 31(2):63-77. doi: 10.1089/jop.2014.0067.
11. Li T., Lindsley K., Rouse B., Hong H. et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a sys¬tematic review and network meta-analysis. Ophthalmology. 2016; 123(1):129-140. doi: 10.1016/j.ophtha.2015.09.005.
12. Chauchan B., Mikelberg F., Balaszi A., LeBlanc R. et al. Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008; 126(8):1030-1036.
13. Singh K., Shrivastava A. Intraocular pressure fluctuations: how much do they matter? Curr Opin Ophthalmol. 2009; 20(2):84-87.
14. Detry-Morel M. Currents on target intraocular pressure and intra¬ocular pressure fluctuations in glaucoma management. Bull Soc Belge Ophtalmol. 2008; 308:35-43.
15. Sit A.J., Asrani S. Effects of medications and surgery on intraocular pressure fluctuation. Surv Ophthalmol. 2008; 53 Suppl1:S45-55. doi: 10.1016/j.survophthal.2008.08.009.
16. Quaranta L., Katsanos A., Russo A., Riva I. 24-hour intraocular pres¬sure and ocular perfusion pressure in glaucoma. Surv Ophthalmol. 2013; 58(1):26-41. doi: 10.1016/j.survophthal.2012.05.003.
17. Drance S.M. The significance of the diurnal tension variations in nor¬mal and glaucomatous eyes. Arch Ophthalmol. 1960; 64:494-501.
18. Duke-Elder S. The phasic variations in the ocular tension in primary glaucoma. Am J Ophthalmol. 1952; 35(1):1-21.
19. Drance S.M. Diurnal variation of intraocular pressure in treated glau¬coma. Significance in patients with chronic simple glaucoma. Arch Ophthalmol. 1963; 70:302-311.
20. Du C., Peng S., Huang W. [Clinical application of the 24 hour IOP monitoring in the diagnose of the normal tension glaucoma suspects]. Yan Ke Xue Bao. 2006; 22(2):68-70, 84.
21. Bergea B., Bodin L., Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology. 1999; 106(5):997-1004; discussion 1004-1005. doi: 10.1016/S0161- 6420(99)00523-0.
22. Asrani S., Zeimer R., Wilensky J., Gieser D., Vitale S., Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an indepen¬dent risk factor in patients with glaucoma. J Glaucoma. 2000; 9(2): 134-142.
23. Bengtsson B., Heijl A. Diurnal IOP fluctuation: not an independent risk factor for glaucomatous visual field loss in high-risk ocular hyper¬tension. Graefes Arch Clin Exp Ophthalmol. 2005; 243(6):513-518. doi: 10.1007/s00417-004-1103-8.
24. Bengtsson B., Leske M.C., Hyman L., Heijl A., Early Manifest Glau¬coma Trial G. Fluctuation of intraocular pressure and glaucoma pro¬gression in the early manifest glaucoma trial. Ophthalmology. 2007; 114(2):205-209. doi: 10.1016/j.ophtha.2006.07.060.
25. Caprioli J. Intraocular pressure fluctuation: an independent risk fac¬tor for glaucoma? Arch Ophthalmol. 2007; 125(8):1124-1125. doi: 10.1001/archopht.125.8.1124.
26. Koscits I.N., Svetlova O.V., Kotlyar K.E. Biomechanical analysis of tra¬ditional modern concepts of primary open-angle glaucoma pathogen¬esis. Glaucoma. 2005; 1:41-59. [In Russ.].
27. Nesterov A.P., Egorov E.A. On the pathogenesis of optic nerve glaucomatous atrophy. Oftalmologicheskiy zhurnal. 1979; 7:419-422. [In Russ.].
28. Quaranta L., Gandolfo F., Turano R., Rovida F. et al. Effects of topi¬cal hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006; 47(7):2917-2923. doi: 10.1167/iovs.05- 1253.
29. Lee P.W., Doyle A., Stewart J.A., Kristoffersen C.J., Stewart W.C. Meta¬analysis of timolol on diurnal and nighttime intraocular pressure and blood pressure. Eur J Ophthalmol. 2010; 20(6):1035-1041.
30. Stewart W.C., Konstas A.G., Kruft B., Mathis H.M., Stewart J.A. Meta¬analysis of 24-h intraocular pressure fluctuation studies and the effi¬cacy of glaucoma medicines. J Ocul Pharmacol Ther. 2010; 26(2):175- 180. doi: 10.1089/jop.2009.0124.
31. Uusitalo H., Chen E., Pfeiffer N., Brignole-Baudouin F. et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010; 88(3):329-336. doi: 10.1111/j.1755-3768.2010.01907.x.
32. Takagi Y., Nakajima T., Shimazaki A., Kageyama M. et al. Pharmaco¬logical characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004; 78(4):767-776. doi: 10.1016/j.exer.2003.12.007.
33. Kurashima H., Asai Y., Aihara M., Ishida N., Nakamura M., Araie M. Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys. J Glaucoma. 2012; 21(2):123-128. doi:10.1097/ IJG.0b013e31820bc9ce.
34. Hamacher T., Airaksinen J., Saarela V., Liinamaa M.J., Richter U., Ropo A. Efficacy and safety levels of preserved and preservative- free tafluprost are equivalent in patients with glaucoma or ocu¬lar hypertension: results from a pharmacodynamics analysis. Acta ophthalmologica Supplement. 2008; 242:14-19. doi: 10.1111/j.1755- 3768.2008.01381.x.
35. Cho S.Y., Kim Y.Y., Yoo C., Lee T.E. Twenty-four-hour efficacy of pre¬servative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure moni¬toring. Jpn J Ophthalmol. 2016; 60(1):27-34. doi: 10.1007/s10384- 015-0413-1.
36. Konstas A.G., Boboridis K.G., Kapis P., Marinopoulos K. et al. 24-Hour efficacy and ocular surface health with preservative-free tafluprost alone and in conjunction with preservative-free dorzolamide/timo- lol fixed combination in open-angle glaucoma patients insufficiently controlled with preserved latanoprost monotherapy. Adv Ther. 2017; 34(1):221-235. doi: 10.1007/s12325-016-0448-9.
37. Konstas A.G., Quaranta L., Katsanos A., Riva I. et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2013; 97(12):1510-1515. doi: 10.1136/bjophthal- mol-2012-303026.
38. Nouri-Mahdavi K., Hoffman D, Coleman A., Liu G et al. Advanced Glaucoma Intervention Study. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004; 111(9):1627-35. doi: 10.1016/j.oph- tha.2004.02.017
39. Nakamoto K., Takeshi M., Hiraoka T., Eguchi M. et al. The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glauco¬ma. Clinical ophthalmology. 2018; 12:359-367. doi: 10.2147/OPTH. S152507.
40. Akaishi T., Shimazaki A., Tonouchi A., Ueda K., Miyawaki N., Kawa- zu K. Benefits of tafluprost and timolol fixed-dose combination for the treatment of glaucoma are confirmed by studies on experimen¬tal animal models. J Ocul Pharmacol Ther. 2015; 31(9):518-524. doi: 10.1089/jop.2015.0031.
41. Fuwa M., Ueda K., Akaishi T., Yamashita N. et al. Advantages of efficacy and safety of fixed-dose tafluprost/timolol combination over fixed-dose latanoprost/timolol combination. PLoS One. 2016; 11(7):e0158797. doi: 10.1371/journal.pone.0158797.
Review
For citations:
Petrov S.Yu., Volzhanin A.V., Kravchik M.V., Mazurova Yu.V., Saparova L.M. Effect of tafluprost on the diurnal intraocular pressure fluctuations in patients with primary open-angle glaucoma. National Journal glaucoma. 2018;17(4):91-96. (In Russ.) https://doi.org/10.25700/NJG.2018.04.08
Views:
736
Email this article 